Cited by 256Alzheimer's disease research and treatmentsHerpesvirus Infections and TreatmentsDementia and Cognitive Impairment Research

Corroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer’s Disease

Open access
Itzhaki, Ruth F.·2018·Frontiers in Aging Neuroscience

Abstract

Strong evidence has emerged recently for the concept that herpes simplex virus type 1 (HSV1) is a major risk for Alzheimer's disease (AD). This concept proposes that latent HSV1 in brain of carriers of the type 4 allele of the apolipoprotein E gene (APOE-ε4) is reactivated intermittently by events such as immunosuppression, peripheral infection, and inflammation, the consequent damage accumulating, and culminating eventually in the development of AD. Population data to investigate this epidemiologically, e.g., to find if subjects treated with antivirals might be protected from developing dementia-are available in Taiwan, from the National Health Insurance Research Database, in which 99.9% of the population has been enrolled. This is being extensively mined for information on microbial infections and disease. Three publications have now appeared describing data on the development of senile dementia (SD), and the treatment of those with marked overt signs of disease caused by varicella zoster virus (VZV), or by HSV. The striking results show that the risk of SD is much greater in those who are HSV-seropositive than in seronegative subjects, and that antiviral treatment causes a dramatic decrease in number of subjects who later develop SD. It should be stressed that these results apply only to those with severe cases of HSV1 or VZV infection, but when considered with the over 150 publications that strongly support an HSV1 role in AD, they greatly justify usage of antiherpes antivirals to treat AD. Three other studies are described which directly relate to HSV1 and AD: they deal respectively with lysosomal changes in HSV1-infected cell cultures, with evidence for a role of human herpes virus type 6 and 7 (HHV6 and HHV7) in AD, and viral effects on host gene expression, and with the antiviral characteristics of beta amyloid (Aβ). Three indirectly relevant studies deal respectively with schizophrenia, relating to antiviral treatment to target HSV1, with the likelihood that HSV1 is a cause of fibromyalgia (FM), and with FM being associated with later development of SD. Studies on the link between epilepsy, AD and herpes simplex encephalitis (HSE) are described also, as are the possible roles of APOE-ε4, HHV6 and HSV1 in epilepsy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnagi.2018.00324

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • HSV-positive individuals have markedly higher risk of developing AD compared to seronegative subjects, and antiviral therapy reduces AD onset.

    “Epidemiological studies indicate that HSV-positive individuals feature markedly higher risk in developing AD compared to seronegative subjects, and antiviral therapy reduced AD onset [533].”
  • In APOE4 carriers, latent HSV-1 is intermittently reactivated by immunosuppression, peripheral infection and inflammation, followed by neurological damage and AD onset.

    “In APOE4 carriers, latent HSV-1 is intermittently reactivated by immunosuppression, peripheral infection and inflammation, followed by neurological damage and AD onset [533].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 75 · Cited by 256

Authors
Itzhaki, R. F.
Affiliations
University of Oxford (GB)
Corresponding author
Itzhaki, Ruth F.
Venue
Frontiers in Aging Neuroscience
Published
2018-10-19
Volume
10
Pages
324-324
ISSN
1663-4365 (ISSN-L)
OpenAlex
W2896110044
Cited by
256
References
75
Citations by year
2026: 19 · 2025: 20 · 2024: 30 · 2023: 16 · 2022: 25 · 2021: 45 · 2020: 62 · 2019: 35 · 2018: 1 · 2017: 2 · 2016: 1
FWCI
4.68
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Aging Neuroscience (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Epidemiology › Herpesvirus Infections and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
herpes simplex virus type 1, Alzheimer's disease, senile dementia, APOE ε4, latent viral reactivation, antiviral therapy, varicella-zoster virus, human herpesvirus 6, human herpesvirus 7, amyloid-beta, host gene expression, fibromyalgia, schizophrenia, herpes simplex encephalitis, epilepsy, inflammation, immunosuppression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review